FDA approves two Vuse e-cigarette models

May.13.2022
FDA approves PMTA review for Vuse brand e-cigarettes - Vibe and Ciro, but not for the popular Alto product.

The U.S. Food and Drug Administration (FDA) has approved PMTA applications for two Vuse brand e-cigarettes, Vibe and Ciro. However, Vuse's best-selling product, Alto, is still undergoing PMTA review.

 

Two models of electronic cigarettes, each with two corresponding battery types, as well as accompanying closed tobacco-flavored pods (Vibe with 3% nicotine, Ciro with 1.5% nicotine), have also been approved.

 

However, Vuse Vibe and Vuse Ciro flavors other than tobacco have not passed PMTA review, meaning they cannot be legally sold.

 

The Vuse Vibe and Ciro devices are outdated models with low sales in the market. In contrast, the NJOY Ace approved through PMTA in April is a more popular product in the market.

 

Earlier, two Vuse products received PMTA approval: the Vuse Solo in October 2021 and the Vuse Logic in March 2022.

 

Source: FDA

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

China’s tobacco regulator names Yao Laiying as top leader
China’s tobacco regulator names Yao Laiying as top leader
China’s tobacco regulator has undergone a top leadership change, according to an official announcement on March 20.
Mar.20
Belarus opts for stricter regulation instead of full e-cigarette ban
Belarus opts for stricter regulation instead of full e-cigarette ban
Belarus rejects full e-cigarette ban, opts for stricter regulation. Officials plan to restrict wholesaling and strengthen import and production permits.
Mar.04 by 2FIRSTS.ai
Imperial Brands to Close Langenhagen Cigarette Factory by 2027
Imperial Brands to Close Langenhagen Cigarette Factory by 2027
Imperial Brands said it will gradually close the Reemtsma factory in Langenhagen near Hanover by 2027 after efforts to find a buyer failed to produce a sustainable agreement. The factory has produced cigarettes since 1971 and currently affects around 600 employees. The company said it had examined all realistic options over recent months but did not receive a binding offer from a potential buyer.
Mar.27 by 2FIRSTS.ai
South Korea’s Revised Tobacco Business Act to Take Effect, With Penalties for Unauthorized Sales
South Korea’s Revised Tobacco Business Act to Take Effect, With Penalties for Unauthorized Sales
With the revised Tobacco Business Act set to take effect on April 24, synthetic nicotine e-cigarettes will be included within the legal definition of tobacco in South Korea. According to information released by Ongjin County, businesses wishing to sell these products must obtain tobacco retailer designation from the relevant authority.
Mar.25 by 2FIRSTS.ai
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
E-cigarette brand MASKKING has recently listed its new UCEE MAX on its official website. According to the website, the device features an open, refillable design with a stated 10 mL e-liquid capacity, supports three refills, and claims a total of 60,000 puffs.
Mar.02 by 2FIRSTS.ai
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai